- Home
- NPFD vs CTNM Comparison
NPFD vs CTNM Comparison
Compare NPFD & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPFD
- CTNM
- Stock Information
- Founded
- NPFD 2021
- CTNM 2009
- Country
- NPFD United States
- CTNM United States
- Employees
- NPFD N/A
- CTNM N/A
- Industry
- NPFD Trusts Except Educational Religious and Charitable
- CTNM
- Sector
- NPFD Finance
- CTNM
- Exchange
- NPFD Nasdaq
- CTNM Nasdaq
- Market Cap
- NPFD 474.6M
- CTNM 248.7M
- IPO Year
- NPFD N/A
- CTNM 2024
- Fundamental
- Price
- NPFD $19.63
- CTNM $12.36
- Analyst Decision
- NPFD
- CTNM Strong Buy
- Analyst Count
- NPFD 0
- CTNM 4
- Target Price
- NPFD N/A
- CTNM $22.75
- AVG Volume (30 Days)
- NPFD 64.7K
- CTNM 281.5K
- Earning Date
- NPFD 01-01-0001
- CTNM 11-05-2025
- Dividend Yield
- NPFD 6.28%
- CTNM N/A
- EPS Growth
- NPFD N/A
- CTNM N/A
- EPS
- NPFD N/A
- CTNM N/A
- Revenue
- NPFD N/A
- CTNM N/A
- Revenue This Year
- NPFD N/A
- CTNM N/A
- Revenue Next Year
- NPFD N/A
- CTNM N/A
- P/E Ratio
- NPFD N/A
- CTNM N/A
- Revenue Growth
- NPFD N/A
- CTNM N/A
- 52 Week Low
- NPFD $14.50
- CTNM $3.35
- 52 Week High
- NPFD $18.07
- CTNM $20.30
- Technical
- Relative Strength Index (RSI)
- NPFD 58.26
- CTNM 73.06
- Support Level
- NPFD $19.59
- CTNM $10.30
- Resistance Level
- NPFD $19.70
- CTNM $13.26
- Average True Range (ATR)
- NPFD 0.13
- CTNM 1.04
- MACD
- NPFD -0.01
- CTNM 0.03
- Stochastic Oscillator
- NPFD 65.46
- CTNM 77.13
About NPFD Nuveen Variable Rate Preferred & Income Fund
Nuveen Variable Rate Preferred&Income is a newly organized, diversified, closed-end management investment company. The Fund's investment objective is to seek to provide a high level of current income and total return.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.